Active Surveillance: From Biology to Bedside Who fails, why, and how can we prevent this?
Dr. Laurence Klotz, MD, argues that active surveillance should continue to be a standard of care for prostate cancer, as long as the urological community takes steps to improve screening methods and reduce overdiagnosis.
Read More